Autologous Stem Cell Transplant Can Improve Survival in MM Patients

Survival in newly diagnosed multiple myeloma improved significantly in patients who underwent early autologous stem cell transplantation (ASCT), according to pooled data from two randomized trials.

The 4-year overall survival was 85% in patients who underwent stem cell transplantation as consolidation therapy versus 76% for those who had transplants after first relapse, reported Federica Cavallo, MD, PhD, of the University of Torino in Italy, and colleagues.

Median time to first progression (PFS1) was almost twice as long in patients who had early stem cell transplantation, and the time to second relapse also was significantly delayed by early transplantation, they said at the European Hematology Association meeting.

Read the original report here: http://bit.ly/V5ycMW

Source: Medpage Today